Sequel Med Tech and Senseonics Holdings announced today a commercial development agreement to integrate Sequel's twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system. This collaboration will create the first AID system compatible with a one-year CGM sensor, offering people with type 1 diabetes unprecedented flexibility in their diabetes management.
The integrated system is expected to be available in the third quarter of 2025, providing patients with a new option that combines long-term glucose monitoring with automated insulin delivery.
A Landmark Integration for Diabetes Management
The partnership brings together two innovative technologies: the twiist AID System, which directly measures insulin volume with each micro-dose, and the Eversense 365, the world's first and only one-year implantable CGM system. This integration aims to enhance diabetes care by offering improved glucose control, increased convenience, and greater flexibility.
"Sequel is committed to investing in innovations that empower people with diabetes with options in how they manage their diabetes," said Sequel CEO and Co-Founder Alan Lotvin, M.D. "By partnering with Senseonics, a company pioneering long-duration CGM, we aim to deliver the flexibility people want to personalize their diabetes management on their terms."
Tim Goodnow, PhD, President and CEO of Senseonics, emphasized the significance of this collaboration: "People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management. The synergy of Eversense and twiist will provide people with diabetes our most recent innovations in advanced pump, algorithm, and sensor technologies."
Expanding Patient Choice in Diabetes Technology
This integration expands the compatibility options for the twiist system, which will now work with both the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor. This gives patients with type 1 diabetes more flexibility to select the CGM system that best suits their individual needs.
The Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system in September 2024, paving the way for its use within an automated insulin delivery system. The sensor is inserted completely under the skin by a healthcare provider and communicates with a smart transmitter worn over the insertion site, automatically sending glucose data every 5 minutes to a mobile app.
Technical Innovations and Clinical Benefits
The twiist AID System, cleared for people ages six and up with type 1 diabetes, features several technical innovations that set it apart from other insulin delivery systems:
- Direct measurement of insulin volume with every micro-dose
- Automatic adjustment of basal insulin delivery based on real-time sensor readings
- Prediction of glucose levels through the twiist Loop algorithm, based on the diabetes community-driven Tidepool Loop
The Eversense 365 offers unique benefits as the only implantable CGM available:
- One full year of exceptionally accurate glucose monitoring
- Minimal interruptions compared to traditional CGMs that require frequent changes
- Reduced calibration requirements (primarily once weekly after day 13)
- Enhanced confidence in decision-making for both patients and healthcare providers
Addressing Unmet Needs in Diabetes Care
For the estimated 1.9 million Americans living with type 1 diabetes, management typically requires frequent glucose monitoring and insulin administration. Traditional CGM systems need replacement every 7-14 days, creating a burden for patients and potential gaps in monitoring during sensor changes.
The integration of a one-year CGM with an automated insulin delivery system addresses several key challenges in diabetes management:
- Reduces the frequency of sensor changes from 26-52 times per year to just once annually
- Minimizes interruptions in glucose data collection
- Allows patients to focus more on living their lives and less on managing their diabetes technology
- Potentially improves adherence and outcomes through simplified management
Market Impact and Availability
The twiist AID System is set to be commercially available in Q2 2025, with the Eversense 365 integration expected in Q3 2025. This timeline positions the integrated system to make a significant impact in the diabetes technology market next year.
Sequel Med Tech, headquartered in Manchester, N.H., was co-founded by Dean Kamen, Pablo Legorreta, Bill Doyle, and Alan Lotvin, MD. The company focuses on developing transformative drug-delivery advancements with a holistic approach to disease management.
Senseonics Holdings, based in Germantown, Md., specializes in long-term implantable glucose management technology. The Eversense 365 is brought to patients through Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation.
Future Implications for Diabetes Technology
This collaboration represents a significant step forward in the evolution of diabetes management technology, potentially setting a new standard for integrated care. By combining long-term monitoring with automated insulin delivery, the system addresses both the monitoring and treatment aspects of diabetes management in a more seamless way than previously possible.
Healthcare providers may benefit from more consistent and comprehensive glucose data, potentially leading to better-informed treatment decisions and improved patient outcomes. For patients, the reduced maintenance requirements could translate to less diabetes management burden and improved quality of life.
As diabetes technology continues to advance, this integration demonstrates how partnerships between innovative companies can address unmet needs and create solutions that weren't previously available to patients with chronic conditions.
